chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient was vaccinated on 2/8/04.  That evening the patient developed a high fever and was brought to the emergency room.  The patient had a seizure and was admitted to Pediatric ICU. Discharge Summary received on 4/26/2005 states otitis media and infection viral.
Brachial Plexus Neuritis - pain in left arm - shoulder to elbow. Started 2 hours after injection.
This spontaneous case was reported by a consumer and describes the occurrence of TINNITUS (tinnitus), DIZZINESS (dizziness), VERTIGO (vertigo) and FEELING ABNORMAL (bbrain fog like when people get COVID-19) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced TINNITUS (tinnitus), DIZZINESS (dizziness), VERTIGO (vertigo) and FEELING ABNORMAL (bbrain fog like when people get COVID-19). At the time of the report, TINNITUS (tinnitus), DIZZINESS (dizziness), VERTIGO (vertigo) and FEELING ABNORMAL (bbrain fog like when people get COVID-19) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant and treatment medications were reported.   This case was linked to MOD21-078918, MOD21-078917, MOD21-078863, MOD21-078916, MOD21-058947, MOD21-078425 (E2B Linked Report).; Sender's Comments:  MOD21-078918: MOD21-078917: MOD21-078863: MOD21-078916: MOD21-058947: MOD21-078425:
pt had a positive COVID test on 2/1/22; presents to the hospital on 2/5/22 via EMS with lethargy, confusion, poor appetite; imaging shows cholecystitis and acute CVA; pt is a no code status; she quickly worsened and went  into cardiac arrest and passed away in the hospital
Facial flushing. HR 72, O2 97%. Slight erythema of L arm injection site. Declined meds. NO SOB, respiratory symptoms.
This spontaneous report was received from a reporter via other company (Control # 60341), concerning a 70 year old female patent with no allergies. Co-suspect and concomitant therapies were not reported. On 24-NOV-2014 at 12:06, the patient was vaccinated with a dose of PNEUMOVAX 23 (dose, dose number and route were not reported) lot # K008410, expiration date 26-FEB-2016. The reporter stated that on 25-NOV-2014, the patient's arm was also inflamed. Patient was told use ice packs on the area as treatment. At the time of the report the outcome was unknown. This is one (1) of three (3) reports from the same source. Additional information has been requested,
pox like rash apppearing over 3 days in medial right arm. Only two on left. All with in C-7 T-1 dermatome
Arrhythmias- Z-patch showed slow Vtach. This aggravated asthma.  Heavy bleeding lasting several weeks a month and still occurring months later- this includes large clots up to palm size.    Appendagitis - unknown if related but had constant diffuse pain and bloating for months
CHILD DEVELOPED MENINGITIS 12JAN91 DUE TO H. FLU TYPE B
flu-like symptoms; weak and run down; felt cold, had her blanket on her; Unplugged; ached real bad/aches and pain; possibly a little bit of a fever; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (flu-like symptoms), ASTHENIA (weak and run down), FEELING COLD (felt cold, had her blanket on her), FEELING ABNORMAL (Unplugged) and MYALGIA (ached real bad/aches and pain) in a 91-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Rheumatoid arthritis and Fibromyalgia.    On 17-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Feb-2021, the patient experienced INFLUENZA LIKE ILLNESS (flu-like symptoms), ASTHENIA (weak and run down), FEELING COLD (felt cold, had her blanket on her), FEELING ABNORMAL (Unplugged), MYALGIA (ached real bad/aches and pain) and PYREXIA (possibly a little bit of a fever). At the time of the report, INFLUENZA LIKE ILLNESS (flu-like symptoms), ASTHENIA (weak and run down), FEELING COLD (felt cold, had her blanket on her), FEELING ABNORMAL (Unplugged), MYALGIA (ached real bad/aches and pain) and PYREXIA (possibly a little bit of a fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The patient was taking unspecified concomitant medications.  Reportedly, the patient did not take any medications for the events however was on a whole lot of other medications (unspecified). The patient started feeling better. Her second dose was scheduled for 17-Mar-2021.
3/2/2021 - Onset of body aches. 3/3/2021 - Increased body aches, left armpit swelling and tenderness, fever 99.1 to 102.1, lost appetite & very tired. 3/4/2021 - Body aches subsided, fever has not gone above 99.0, left armpit still swollen and tender, still experiencing low appetite and energy.
When I received both the 1st and 2nd doses of the vaccine I was in good health. I was walking and jogging 6 miles a day. The minute I received the vaccines I got a metallic taste in my mouth, flush and then felt sick for an hour. That went away both times. However I have had muscle cramping and severe fatigue and aching since the 1st dose and have not been able to walk more than a few blocks or exercise since. It has now been 3.5 months of waiting for the flu-like symptoms to go away. My muscles go into cramps doing small things like stairs or an incline on the street or even just house cleaning getting up and down and I get out of breath. I have been to the doctor and cannot find the cause.
Patient is a healthy 40 y/o female who received J&J vaccine on 4/7/21. She started having intermittent fevers and headaches 24-48 hours after. Headache became so bad she seeked medical attention on 4/16/21, and was found to be profoundly thrombocytopenic. She additionally had a CT scan that was concerning for a right sided subdural/epidural fluid collection and a MRI that confirmed that she had multiple epidermoid cysts. A full thrombocytopenia workup was completed and the patient was diagnosed with ITP and started on high dose steroids and IVIG. Patient's lowest platelet count was 9K.
We discovered that a patient received only one component of the Menveo vaccine on 7/27/20. The MenA lyophilized conjugate vaccine component was reconstituted with sterile water and administered to the patient.  The patient did not receive the MENCYW-135 liquid conjugate vaccine component.
Elevated temp, Rash on throat/neck area, Arms stiffness in joints, Joint pains,especially legs Benadryl ordered.
A report has been received from a Pharmacist concerning a 7 month old, Female subject, who received FLUMIST quadrivalent (intranasal), 0.2 Millilitres. FLUMIST quadrivalent (intranasal) started on an unknown date. The Pharmacist reports that FLUMIST was administered to a 7 month old girl 2 days ago. The outcome of administration to 7 mo old is unknown. The report was considered to be non-serious.
Tested extremely positively on day 10; Tested extremely positively on day 10; Congestion; Lingering dry throat; Sinus pain; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 31-year-old male patient received BNT162b2 (BNT162B2), on 07Apr2021 at 13:00 as dose 1, single (Lot number: Ew0151), in left arm and on 30Apr2021 at 11:00 as dose 2, single (Lot number: Ea8736) at the age of 30 years, in left arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 11Nov2021 at 18:00 as dose 3 (booster), single (Lot number: 067F21A), in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: NASAL CONGESTION (non-serious) with onset 07May2022 at 08:00, outcome "recovering", described as "Congestion"; DRY THROAT (non-serious) with onset 07May2022 at 08:00, outcome "recovering", described as "Lingering dry throat"; SINUS PAIN (non-serious) with onset 07May2022 at 08:00, outcome "recovering"; VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 07May2022 at 08:00, outcome "recovering" and all described as "Tested extremely positively on day 10". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (28Apr2022) I took paxlovid on the first day of my positive; (08May2022) Tested extremely positively on day 10. Therapeutic measures were taken as a result of covid-19. Therapeutic measures were not taken as a result of nasal congestion, dry throat, sinus pain.  Clinical course: No other medication patient received in 2 weeks. Patient administered Paxlovid from 28Apr2022 to 03May2022 for the treatment of COVID-19. Patient took paxlovid on the first day of his positive test and ran the full series. By day 5, he was no longer exhibiting any symptoms except for a lingering dry throat, and he started testing negative on day 8. On day 9 he had congestion and sinus pain, and tested extremely positively on day 10.
Delayed second shingrix dose / first dose on Nov 25th 2019; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 93-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received in 25th November 2019).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were provided as follows: Age at vaccination was not applicable for this report. The reporter inquired about delayed 2nd dose of Shingrix.  Till the date of reporting, the patient did not receive the 2nd dose of Shingrix, which led to incomplete course of vaccination. The reporter asked should the series be continued or restarted. The reporter did not consent to follow-up.
Seven post vax administration, this child began to have seizures. Her grandmother called the manufacturer and described the seizures as stiffening of the arms and legs followed by shaking of the torso for about 3 seconds. The child would seem unaware that anything had happened and would continue her activity after the seizure. At first this occurred once daily, but the frequency has increased over time, according to the grandfather. Treatment being sought through hospital. Tests are pending.
Two weeks after receiving hep b #1 in left deltoid, pt reports redness, swelling, and discomfort on right gums (both up and down). Next day swelling was noted by pt in the right neck area. Pt went to her dentist who performed x-rays put pt on oral antibiotics and mouth rinse. Symptoms resolved in about a week.
Patient age 16 was given Janssen (J&J) vaccine at a Mobile site.  Age for Janssen is 18.
Smell loss; Taste loss; Joint pain; This spontaneous case was reported by a consumer and describes the occurrence of ANOSMIA (Smell loss), AGEUSIA (Taste loss) and ARTHRALGIA (Joint pain) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 24-Apr-2021 at 10:38 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Apr-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced ARTHRALGIA (Joint pain). On an unknown date, the patient experienced ANOSMIA (Smell loss) and AGEUSIA (Taste loss). At the time of the report, ANOSMIA (Smell loss) and AGEUSIA (Taste loss) had not resolved and ARTHRALGIA (Joint pain) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were mentioned. No treatment details were reported.
Initial report received from a health care professional (nurse) on 17 Aug 2010: On 15 Aug 2010, this patient was vaccinated with only the MenCYW liquid conjugate of MENVEO (batch number: 091101), (dose: 0.5 ml) intramuscularly without being reconstituted with the MenA conjugate component. No adverse events were noted following this medication error.
This spontaneous report was received from a nurse practitioner via the company representative regarding a 17 year old female patient. The patient's concurrent conditions, medical history and concomitant medications were not reported. On an unknown date approximately in June 2013, the patient was vaccinated with GARDASIL injection, dose 1, intramuscular (strength, lot # and expiration date unknown). On an unknown date approximately in June 2013, the patient experienced anaphylactic reaction immediately after receiving the first dose of GARDASIL. No product quality issue was involved. The outcome of anaphylactic reaction was reported as recovered on an unknown date. Causality assessment was not provided by the reporter. Upon internal review, anaphylactic reaction was determined to be medically significant. Additional information has been requested.
Approximately 5 hours after receiving 6 month vaccines, he developed hives to arms and legs.  No respiratory symptoms.
First Exaggerated PVC?s, then rapid heart beat up to 122 on my walk, then chills and then fever of 100.6, then urticaria the size of half my foot under the injection site. The pvc?s lasted a month. The fever gone by bedtime. Rapid heart rate abated the following day.
felt like I was ready to collapse; increased effort to breathe; I have been deathly sick for two weeks; This is a spontaneous report from a non-contactable consumer (patient). This consumer reported different events after different doses of vaccine. This is the second of 2 reports. This 76-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on 18Feb2021 at single dose for COVID-19 immunisation. Relevant medical history and concomitant medications were not reported. After the first dose of the BNT162B2 vaccine, given on 28Jan2021, the patient experienced dizziness, dry cough, sneezing, no taste, nausea, tiredness and headache. After the second dose, the patient reported that "it elevated completely". The patient stated that on an unspecified date after the second dose "I have been deathly sick for two weeks". She reported also an increased effort to breathe and "felt like I was ready to collapse". The outcome of the events was unknown.  No follow-up attempts are possible. Information about lot/batch number cannot be obtained.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021245359 same patient, different dose/AE
Pt and other foster home residents and CGs received COVID shot #1 at 11:30 am within the foster home after POA consented to pt's vax. At ~9p, CG heard pt vocalize a loud sound, CG checked on him and entire body and stomach so rigid, lips were pressed together/pale and pale throughout. Stopped breathing for a few seconds. CG couldn't get BP or pulse initially. Say tears rolling down face.  87/45, 56, 97.2F, 91% on RA. After 10 mins was 129/53, 48, 91%. Called 911, 79/47, couldn't get pulse.  Due to POLST comfort measures, EMS did not transfer pt to ER. After EMS left, pt "came to" again, pt signed EMS consent NOT to be transferred to ER.  Pt's POA didn't pick up the phone. Current VS:  111/64, 69, afebrile. POA does not want pt to receive the second COVID shot.
Information has been received from a physician as part of a market research focus group concerning a 16 year old female patient who on an unknown date was vaccinated with a second dose of GARDASIL (lot number, site and route not reported). Subsequently the patient developed redness of skin, shortness of breath, dizziness and nausea after received the second dose of GARDASIL. Therapy with GARDASIL was discontinued. At the time of report, the patient had recovered. Additional information has been requested.
patient developed pain and swelling of left forearm after covid vaccination. He had a h/o an old clot in this arm approximately 1 year ago which had resolved.  he was diagnosed with a left cephalic vein thrombosis 4.14.2021 and was to use warm compresses and NSAIDS
Coughing up mucus; This is not a good feeling; Coughing all through the night; Been sick with headache; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 22-May-2021 and was forwarded to Moderna on 24-May-2021.    Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of SECRETION DISCHARGE (Coughing up mucus), MALAISE (This is not a good feeling), COUGH (Coughing all through the night) and HEADACHE (Been sick with headache) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Apr-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SECRETION DISCHARGE (Coughing up mucus), MALAISE (This is not a good feeling), COUGH (Coughing all through the night) and HEADACHE (Been sick with headache). At the time of the report, SECRETION DISCHARGE (Coughing up mucus), MALAISE (This is not a good feeling), COUGH (Coughing all through the night) and HEADACHE (Been sick with headache) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was withdrawn on an unknown date.       No concomitant medication was provided.  No treatment medication information was provided.
Day after shot, I experienced flu-like symptoms. I experienced a high fever and body aches. On the 13th of April, I began to experience severe dizziness, vertigo, and blurred vision. I have been experiencing this everyday since the 13th of April. I was submitted to the hospital on April 16th due to severe dizziness and blurred vision. The diagnosis was BPPV (benign paroxysmal positional vertigo) and I received 0.9% NaCl (NS) and Meclizine (Antivert). I am still experiencing severe dizziness and vertigo.
Hives appeared on vaccination site, spread throughout the night, onto opposite leg, stomach and chest.  Benadryl cream used with no affect.
I am the breastfeeding mother of baby.  The morning after my second covid dose my daughter got a rash around her mouth. That afternoon she had terrible diarrhea and that night she ran a fever for a few hours. Over the course of the next few days the rash came and went and she had bad gas and more diarrhea.
States "My arm (Rt.) was sore from shoulder to elbow - area throbbed - went to urgent care center - received and took anti-inflammatory med. x 3-4 days - better after that."
Patient received vaccine after having received a Hepatitis A vaccine and shingles vaccine on March 2nd, 2021. This is within 14 days of each other, which is not recommended at this time.
Sx: Pt reported rash at injection site. Rash continued to spread and he was seen at ER 5-8-14. On 5-9-14 pt spoke to MD and was admitted to hospital.
Injection site red and itchy after 1st dose; Injection site red and itchy after 1st dose; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (Injection site red and itchy after 1st dose) and VACCINATION SITE ERYTHEMA (Injection site red and itchy after 1st dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PRURITUS (Injection site red and itchy after 1st dose) and VACCINATION SITE ERYTHEMA (Injection site red and itchy after 1st dose). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL A) at an unspecified dose and frequency. At the time of the report, VACCINATION SITE PRURITUS (Injection site red and itchy after 1st dose) and VACCINATION SITE ERYTHEMA (Injection site red and itchy after 1st dose) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported.  Treatment for the events included Benadryl, which helped.
Extreme fatigue, feeling faint, pain in joints and back, chills, fever of 102.
PATIENT HAD IMMUNIZATION ON 3/13/2012 IN RIGHT DELTOID.  PATIENT DEVELOPED REDNESS/SWELLING/PAIN TO HIS RIGHT DELTOID.  SEEN BY PROVIDER INSTRUCTED TO APPLY WARM COMPRESS TO AREA.
Influenza virus received on 10/18/02. Immediately after the injection, the site was itchy. After about 10 minutes, itching subsided. The following day, the injection site developed a hardened spot around it. The spot (area) is still hard today, measuring approximately 1"x1".
Patient is 41 year old male who had the Anthrax #1 and initially had some local tenderness for the first 72 hours.  The area seemed normal for about one week and then it started to swell again.  He reports tenderness at the sight.  No fevers or chills.  No body aches and no nausea or vomiting.  No dizziness or lightheadedness.  He has never had a reaction like this before.  He reports the swelling seems to be getting worse each day.  He is scheduled for number 2 later this week.
Vaccine - given 2-11-14. Symptoms started evening 2-11-14. Feverish, achy joints, raspy throat.
Patient presented to the ER with a chief complaint fever and myalgias, found to have severe neutropenia and neutropenic fever. She was started on doxycycline for concern for tick-borne illness, but serologies have returned negative. Her counts recovered spontaneously and her fevers resolved.